JadiCell is under clinical development by Therapeutic Solutions International and currently in Phase I for Traumatic Brain Injury. According to GlobalData, Phase I drugs for Traumatic Brain Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the JadiCell LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JadiCell overview
Stem cell therapy is under development for the treatment of traumatic brain injury, Coronavirus Disease 2019 (COVID-19) associated acute respiratory distress syndrome and acute lung injury, chronic obstructive pulmonary disease and chronic traumatic encephalopathy. It is administered through intravenous route. The drug candidate consists of universal donor adult mesenchymal stem cells generated from umbilical cords.
Therapeutic Solutions International overview
Therapeutic Solutions International (Therapeutic Solutions) is a pharmaceutical company that focused on on immune modulation for the treatment of several specific diseases. The company product pipeline includes DermalStilbene, NanoStilbene and ProJuvenol. Its ProJuvenol consists of anti-aging ingredients which helps for a healthy functionality for everyday living and promotes cellular rejuvenation. The company offers products in forms of syrups and capsules. Therapeutic Solutions also offers anti-ageing vitalization dietary supplement which increases the bone density, optimize hormone levels for body shaping, reduce fat, improve muscle tone, increase libido and sexual function and decrease symptoms of stress and anxiety. Therapeutic Solutions is headquartered in Oceanside, California?, the US.
For a complete picture of JadiCell’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
